Literature DB >> 27815791

Comparative Study of Different Nano-Formulations of Curcumin for Reversal of Doxorubicin Resistance in K562R Cells.

Tapan K Dash1, V Badireenath Konkimalla2.   

Abstract

PURPOSE: Curcumin is very well established as a chemo-therapeutic, chemo-preventive and chemo-sensitizing agent in diverse disease conditions. As the isolated pure form has poor solubility and pharmacokinetic problems, therefore it is encapsulated in to several nano-formulations to improve its bioavailability. Here in the current study, we aim to compare different nano-formulations of curcumin for their chemo-sensitizing activity in doxorubicin (DOX) resistant K562 cells.
METHODS: Four different curcumin formulations were prepared namely DMSO assisted curcumin nano-dispersion (CurD, 260 nm), liposomal curcumin (CurL, 165 nm), MPEG-PCL micellar curcumin (CurM, 18 nm) and cyclodextrin encapsulated curcumin (CurN, 37 nm). The formulations were subjected to particle characterizations (size, zeta potential, release studies), followed by biological assays such as cellular uptake, P-gp inhibitory activity and reversal of DOX resistance by co-treatment with DOX.
RESULTS: Curcumin uptake in K562N and K562R cells was mildly reduced when treated with CurL and CurM, while for CurD and CurN the uptake remained equivalent. However, CurL retained P-gp inhibitory activity of curcumin and with a considerable chemo-sensitizing effect but CurM showed no P-gp inhibitory activity. CurN retained above biological activities, but requires a secondary carrier under in vivo conditions.
CONCLUSIONS: From the results, CurM was found to be most suitable for solubilization of curcumin where as CurL can be considered as most suitable nano-formulation for reversal of DOX resistance.

Entities:  

Keywords:  HP-β-CD; MPEG-PCL; P-glycoprotein; liposomes; nano-formulation

Mesh:

Substances:

Year:  2016        PMID: 27815791     DOI: 10.1007/s11095-016-2060-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  43 in total

1.  Molecular inclusion complex of curcumin-β-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel.

Authors:  Heni Rachmawati; Citra Ariani Edityaningrum; Rachmat Mauludin
Journal:  AAPS PharmSciTech       Date:  2013-08-29       Impact factor: 3.246

2.  Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Qing-Long Guo; Yan Jiang; Guo-Qing Liu
Journal:  Biol Pharm Bull       Date:  2005-10       Impact factor: 2.233

3.  Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake.

Authors:  Vivek R Yadav; Sahdeo Prasad; Ramaswamy Kannappan; Jayaraj Ravindran; Madan M Chaturvedi; Lauri Vaahtera; Jaakko Parkkinen; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  Fabrication of Curcumin Micellar Nanoparticles with Enhanced Anti-Cancer Activity.

Authors:  Wing-Hin Lee; Mary Bebawy; Ching-Yee Loo; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  J Biomed Nanotechnol       Date:  2015-06       Impact factor: 4.099

5.  Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention.

Authors:  Iris E Allijn; Raymond M Schiffelers; Gert Storm
Journal:  Int J Pharm       Date:  2016-04-29       Impact factor: 5.875

6.  Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.

Authors:  Byeong Hyeok Choi; Chang Gun Kim; Yoongho Lim; Soon Young Shin; Young Han Lee
Journal:  Cancer Lett       Date:  2007-11-19       Impact factor: 8.679

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin.

Authors:  Yasuyuki Sadzuka; Makiko Nagamine; Tatsushi Toyooka; Yuko Ibuki; Takashi Sonobe
Journal:  Int J Pharm       Date:  2012-04-28       Impact factor: 5.875

9.  Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer.

Authors:  N Rocks; S Bekaert; I Coia; G Paulissen; M Gueders; B Evrard; J-C Van Heugen; P Chiap; J-M Foidart; A Noel; D Cataldo
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

10.  Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer.

Authors:  Bi-Lan Wang; Yong-mei Shen; Qiong-wen Zhang; Yu-li Li; Min Luo; Ze Liu; Yan Li; Zhi-yong Qian; Xiang Gao; Hua-shan Shi
Journal:  Int J Nanomedicine       Date:  2013-09-24
View more
  1 in total

1.  Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.

Authors:  Tapan K Dash; V Badireenath Konkimalla
Journal:  Pharm Res       Date:  2017-05-23       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.